Aquestive Therapeutics(TSX:Not available)
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
Investor website: https://aquestive.com/
About
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. With proprietary technologies like PharmFilm® and AdrenaVerse™, we’re advancing patient-friendly alternatives to inconvenient or invasive therapies, including investigational treatments for anaphylaxis and potentially alopecia areata. Our expertise spans the full product lifecycle, from formulation to commercialization, with four commercialized products marketed by our licensees in the U.S. and around the world. We have the expertise to manufacture and package a wide range of pharmaceutical products, including oral films, creams, and lotions, for our contract licensees and customers. Since the inception of the Company, we have been committed to our purpose: developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.
Verified company data
- Cash position
- $110.7 million
- Shares outstanding
- 99,723,635
- Fully diluted shares
- N/A
- Projects
- ["Anaphylm™ (dibutepinephrine) sublingual film is the first orally delivered film formulation of epinephrine in clinical development for the emergency treatment of severe allergic reactions, including anaphylaxis. Developed using both of Aquestive's core technologies (PharmFilm® and AdrenaVerse™), Anaphylm™ is designed to deliver rapid, effective treatment without the need for injection. Compact, portable, and easy to administer, Anaphylm™ begins to dissolve on contact and requires no water or swallowing—ideal for real-world emergencies.","Libervant (diazepam) buccal film is the first and only orally-administered, non-device diazepam product candidate treatment for seizure clusters (also known as acute repetitive seizures) in children ages 2-5 years and in patients 12 and older. Delivered using Aquestive’s proprietary PharmFilm® technology, Libervant is a discreet, mint-flavored film that dissolves when placed inside the cheek, requiring no swallowing, chewing, or additional liquids. It offers a simple, syringe-free alternative to rectal delivery, with consistent absorption and demonstrated ease of use."]
- Leadership
- Dan Barber (Chief Executive Officer, President and Director, Appointed CEO in May 2022 after serving as COO since May 2019. Joined Aquestive in 2007, instrumental in the growth of the company and oversight of product launches.), Peter Boyd (Chief People Officer), Melina T. Cioffi, Pharm.D. (Senior Vice President – Regulatory Affairs), Matthew W. Davis, M.D., RPh (Chief Development Officer), Matthew Greenhawt, M.D. (Chief Medical Officer), Cassie Jung (Chief Operating Officer), Sherry Korczynski (Chief Commercial Officer), Ernie Toth (Chief Financial Officer), Thomas A. Zalewski (Chief Legal Officer and Chief Compliance Officer), Gregory B. Brown, M.D. (Chair of the Board, Director and Co-founder of HealthCare Royalty Partners), John Cochran (Director, Partner at Bratton Capital Management L.P., Partner and COO of Crestline Investors, Inc.), Abigail L. Jenkins (Director, former Director and President & CFO of Gamida Cell Ltd.), Julie Krop, M.D. (Director, Chief Medical Officer of DiaMedica Therapeutics, Inc.), Timothy E. Morris (Director, Chief Operating Officer of Humanetics Corporation), Marco Taglietti, M.D. (Director, Chief Executive Officer of NanoNewron)
Verified data last updated: 2026-07-10